Schizophrenia Patients Have an Option with Iloperidone

Schizophrenia Patients Have an Option with Iloperidone

SchizophreniaIloperidone, CAS# 133454-47-4 is an antipsychotic medication. Known as the brand name Fanapt, the patent for this efficacious medication expires for Novartis on November 15, 2016. Iloperidone is available as tablets in dosages of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg, and is intended primarily for the treatment of schizophrenia. With more than 3.2 million Americans today suffering from Schizophrenia, this is an essential treatment. Iloperidone is typically given as an increasing dosage over the course of 7 days in a special starter pack. The starting low dose is important as it helps the patient avoid potential adverse effects like light-headedness or fainting.

On August 9, 2012 Vanda Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, announced that the Israeli Ministry of Health (MoH) granted market approval for Fanapt, or Iloperidone,  for the treatment of schizophrenia.  This exciting news comes on the heels of a recently released study investigating  why certain drugs have mixed success in treating schizophrenia, and tend to lose their effectiveness. This study, reported in the journal Nature Neuroscience, focused on scientific research which investigated the external genetic reasons, or epigenetic factors, that cause treatment-resistance to atypical antipsychotic drugs. Recent statistics gleaned from researchers at Mount Sinai School of Medicine revealed that 30% of patients with schizophrenia do not respond to currently available treatments. This was due to an enzyme called HDAC2, which was highly expressed in the brains of mice chronically treated with antipsychotic drugs, resulting in lower expression of the receptor called mGlu2. It is believed that the enzyme in the brains of schizophrenic patients begins to compensate for the prolonged chemical changes over time that are caused by antipsychotics, which results in a decrease in their efficacy. However, antipsychotic medications are currently the only viable treatment for this devastating mental illness. This information only solidifies the need for new and unique treatments for schizophrenia. Worldwide about 1% of the population is diagnosed with schizophrenia, and about 1.5 million people will be diagnosed with schizophrenia this year around the globe. New instances of this illness are most likely to occur in early adulthood, with a peak in patients between the ages of 16 and 25 years of age.

LGM Pharma provides API Iloperidone for research and development purposes, and offers continual support to clients throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service